Rossari Biotech Ltd's Q4FY25 Quarterly Results

Result Summary

• Rossari Biotech Ltd reported a 7.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 15.6%.
• Its expenses for the quarter were down by 9.2% QoQ and up 14.9% YoY.
• The net profit increased 7.7% QoQ and increased 17.8% YoY.
• The earnings per share (EPS) of Rossari Biotech Ltd stood at 6.2 during Q4FY25.

Financial Statments for Q4FY25

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Rossari Biotech Ltd is a company engaged in the specialty chemicals industry. The company primarily focuses on manufacturing a wide range of products including textile specialty chemicals, animal health and nutrition products, and home, personal care, and performance chemicals. As a prominent player in the specialty chemicals space, Rossari Biotech has a diversified product portfolio catering to various industries. It operates within a competitive landscape where innovation and sustainability play crucial roles. Recent major developments concerning Rossari Biotech Ltd or specific changes in its business strategy are not available within the provided data.

Revenue

During Q4FY25, Rossari Biotech Ltd recorded a total income of ₹473.10 crores. This marks a decrease of 7.8% from the previous quarter (Q3FY25), where total income was ₹513.28 crores. However, when compared to the same period last year (Q4FY24), there is a year-over-year increase of 15.6%, as total income in Q4FY24 was ₹409.27 crores. The year-over-year growth suggests an improvement in revenue generation compared to the previous year, despite a quarter-over-quarter decline.

Profitability

In terms of profitability, Rossari Biotech Ltd's profit before tax (PBT) for Q4FY25 stood at ₹45.38 crores, reflecting a 7.9% increase from ₹42.05 crores in Q3FY25. Comparatively, the PBT in Q4FY24 was ₹37.03 crores, resulting in a year-over-year growth of 22.5%. The tax expense for Q4FY25 was ₹11.44 crores, showing a 7.1% increase from the previous quarter and a 38.7% increase from the same quarter last year. The profit after tax (PAT) amounted to ₹34.13 crores in Q4FY25, which is a 7.7% rise from Q3FY25's ₹31.70 crores and a 17.8% increase from ₹28.98 crores in Q4FY24. Earnings per share (EPS) also increased to ₹6.20, marking an 8.8% quarter-over-quarter growth and a 19.2% year-over-year growth.

Operating Metrics

The total expenses for Rossari Biotech Ltd in Q4FY25 were reported at ₹427.71 crores, which represents a 9.2% decrease from Q3FY25 when expenses were ₹471.23 crores. When compared to Q4FY24, where total expenses were ₹372.25 crores, there is a 14.9% increase year-over-year. This suggests a broad trend of rising costs over the year, despite a reduction in expenses in the latest quarter. The financial data reflects an improvement in profitability metrics such as profit before tax, profit after tax, and earnings per share on both a quarterly and annual basis, indicating efficient cost management and revenue utilization. The specific financial ratios such as P/E ratio, debt-to-equity ratio, and current ratio are not provided in the data, thus not included in this analysis.